Tech Company Financing Transactions

Biohaven Pharmaceuticals Funding Round

Venrock, Aisling Capital and Aperture Venture Partners participated in a $80 million capital raise for Biohaven Pharmaceuticals. The round was announced on 11/2/2016.

Transaction Overview

Announced On
Transaction Type
Venture Equity
Proceeds Purpose
Proceeds from this financing will be used to advance the company's late stage clinical programs in orphan neurologic indications and other trials in areas of large unmet medical needs. Biohaven plans to initiate Phase 2/3 studies in 4Q2016 and in 2017.

Company Information

Company Status
Mailing Address
215 Church St.
New Haven, CT 06510
Email Address
Not Recorded
Biohaven Pharmaceuticals (NYSE: BHVN) is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders.
Biohaven Pharmaceuticals LinkedIn Company Profile
Social Media
Biohaven Pharmaceuticals Company Twitter Account
Company News
Biohaven Pharmaceuticals News
Biohaven Pharmaceuticals on Facebook
Biohaven Pharmaceuticals on YouTube

Management Team

Email & Social
Chief Executive Officer
Vlad Coric
  Vlad Coric LinkedIn Profile  Vlad Coric Twitter Account  Vlad Coric News  Vlad Coric on Facebook
Chief Financial Officer
James Engelhart
  James Engelhart LinkedIn Profile  James Engelhart Twitter Account  James Engelhart News  James Engelhart on Facebook
Chief Medical Officer
Robert Berman
  Robert Berman LinkedIn Profile  Robert Berman Twitter Account  Robert Berman News  Robert Berman on Facebook
Chief Scientific Officer
Charlie Conway
  Charlie Conway LinkedIn Profile  Charlie Conway Twitter Account  Charlie Conway News  Charlie Conway on Facebook
David Loomis
  David Loomis LinkedIn Profile  David Loomis Twitter Account  David Loomis News  David Loomis on Facebook
VP - Bus. Development
Robert Croop
  Robert Croop LinkedIn Profile  Robert Croop Twitter Account  Robert Croop News  Robert Croop on Facebook
VP - Bus. Development
Donnie McGrath
  Donnie McGrath LinkedIn Profile  Donnie McGrath Twitter Account  Donnie McGrath News  Donnie McGrath on Facebook
VP - Bus. Development
Elyse Stock
  Elyse Stock LinkedIn Profile  Elyse Stock Twitter Account  Elyse Stock News  Elyse Stock on Facebook
VP - Operations
Lia Donahue
  Lia Donahue LinkedIn Profile  Lia Donahue Twitter Account  Lia Donahue News  Lia Donahue on Facebook
VP - Operations
Kim Gentile
  Kim Gentile LinkedIn Profile  Kim Gentile Twitter Account  Kim Gentile News  Kim Gentile on Facebook
VP - Operations
Meghan Lovegren
  Meghan Lovegren LinkedIn Profile  Meghan Lovegren Twitter Account  Meghan Lovegren News  Meghan Lovegren on Facebook
VP - Operations
Beth Morris
  Beth Morris LinkedIn Profile  Beth Morris Twitter Account  Beth Morris News  Beth Morris on Facebook
VP - Regulatory Affairs
Marianne Frost
  Marianne Frost LinkedIn Profile  Marianne Frost Twitter Account  Marianne Frost News  Marianne Frost on Facebook



Browse more venture capital transactions:

Prev: 11/2/2016: venture capital transaction
Next: 11/2/2016: Endgame venture capital transaction


Share this article


About Our Venture Capital Transactions Database

We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary